A novel brain-selective MAO inhibitor, Ladostigil can selectively reverse the behavioral and neurochemical effects induced by prenatal stress without affecting the behavior of controls. Antidepressant.
Ladostigil, a carbamate is also a butyryl cholinesterase (BuChE) inhibitor. It possesses anti-inflammatory property and effectively reduces the levels of tumor necrosis factor α (TNF-α) in lipopolysaccharide (LPS)-activated macrophages. It provides protection to cardiomyocytes. Ladostigil has neuroprotective functionality and has the potential to tre at mild cognitive impairment (MCI) and spatial memory deficits development. It also exhibits protective effects during oxidative and nitrative stress.', 'Multifunctional drug designed to tre at Alzhemierμs disease by combining in a single molecule the neuroprotective/neurorestorative effects of the (MAO)-B inhibitor rasagiline with the cholinesterase (ChE) inhibitory activity of rivastigmine.
Ladostigil (17 mg/kg; p.o. daily for 6 weeks) hemitartrate abolishes their hyperanxiety and depressive-like behaviour in the elevated plus maze (EPM) and forced swim tests (FST) tests in adulthood from puberty to prenatally-stressed rats[4].
Ladostigil (50 μmol/kg; single p.o.) hemitartrate restores the loss of episodic memory in the object recognition test in rats[3].
| Animal Model: | Pathogen-free (SPF) Sprague-Dawley rats[4] |
| Dosage: | 17 mg/kg |
| Administration: | P.o. (added to the drinking water) daily for 6 weeks |
| Result: | Inhibited brain MAO-A and B by more than 60%.
Reduced hyperanxiety of male and female prenatally stressed (PS) rats in the EPM and depressive-like behaviour in the FST.
|
MAO-B: 37.1 nM (IC50); AChE: 31.8 nM (IC50)
